A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor
Bristol-Myers Squibb
Study ID
NCT06487156
Status
Active Not Recruiting

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to collect and evaluate real-world data to describe the outcomes, patient characteristics, safety profile and treatment patterns of first-line nivolumab plus ipilimumab treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) in Italy

Key Dates

Start date
Oct 11, 2023
Status verified
Jan 2026
Primary completion
Oct 11, 2030
Completion
Oct 11, 2030

Study Design

Enrollment
404 participants (actual)

Arms

  • Arm: Participants receiving first-line nivolumab plus ipilimumab

Primary Outcome Measure

Overall survival (OS) [ Time Frame: Up to 5 years ]

Related Studies